NeuroPace, Inc. (NPCE)

In the past six months, NeuroPace's stock has experienced several notable events. As of October 16, 2025, the share price was $10.66, an increase from $6.39 on October 17, 2024. In Q2 2025, NeuroPace reported record quarterly revenue of $23.5 million, a 22% year-over-year growth, with the gross margin increasing to 77.1%. Despite beating revenue estimates, the company reported a Q2 loss of ($0.26) earnings per share, missing the consensus estimate of ($0.24). Following these results, NeuroPace increased its 2025 revenue guidance to $94-98 million and raised its gross margin forecast to 75-76%. Wells Fargo & Company reduced their price objective for NeuroPace from $17.00 to $15.00, while maintaining an "overweight" rating, and Zacks Research also lowered NeuroPace from a "strong-buy" to a "hold" rating. NeuroPace announced a refocusing of its product portfolio, stating that this would not change its previously stated 2025 revenue guidance or its long-range plan expectations. NeuroPace successfully completed an underwritten public offering of common stock, securing approximately $74.8 million. Shares of NeuroPace saw a strong rally towards the end of 2023 and early 2024, doubling since September 2023. In November, NeuroPace reported Q3 sales of $16.4 million, up 47% year-over-year, with operating losses narrowing, and announced a strategic collaboration to leverage the RNS System's biomarker monitoring and data analysis capabilities. KCK LTD., a significant shareholder, sold 4,082 shares of NeuroPace common stock at $6.0885 per share, totaling $24,853.

Demand seasonality for NeuroPace's products and services has been noted, with slower sequential sales growth in Q3 attributed to seasonality. A transition to longer-lasting devices can also impact sales patterns. The company's revenue is primarily derived from the sales of the RNS System to hospital facilities for initial implant procedures and replacement procedures, and the demand for these procedures can be influenced by factors such as patient and physician scheduling, insurance approvals, and hospital budgeting cycles. The company's estimates of future demand for a particular product are judgmental and can impact inventory reserves.

NeuroPace, Inc. is a medical device company based in Mountain View, California, specializing in neurostimulation technology to improve the lives of individuals with neurological disorders, primarily drug-resistant focal epilepsy. The company operates within the Healthcare sector and the Medical Devices industry. NeuroPace's flagship product is the RNS® System, a brain-responsive neuromodulation system designed to treat drug-resistant epilepsy by monitoring brain activity in real-time and delivering personalized electrical stimulation to prevent seizures. The RNS System includes an RNS neurostimulator, cortical strip and depth leads, and a Patient Remote Monitor, along with other implantable and non-implantable accessories. Beyond the hardware, NeuroPace also provides a physician tablet, a patient data management system, and the nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. The company sells its products to hospital facilities for both initial RNS System implant procedures and replacement procedures.

NeuroPace, Inc. primarily operates and sells its products in the United States. The company is headquartered in Mountain View, California.

NeuroPace's brand reputation appears to be generally positive within the medical community, particularly concerning its RNS System for epilepsy treatment. The company is seen as a leader in neurotechnology and is committed to advancing the field of neuromodulation through continuous innovation and clinical research. Wall Street analysts have a "Moderate Buy" consensus rating for NeuroPace, with an average 12-month price target of $16.60. Strong revenue growth contributes positively to the company's reputation, indicating market acceptance and demand for its products. NeuroPace's strategic collaboration to leverage the RNS System's biomarker monitoring and data analysis capabilities further enhances its reputation as an innovative company. Recent strategic additions to the leadership team are viewed as pivotal for the company's expansion plans, suggesting a focus on strengthening internal capabilities and market reach.

NeuroPace, Inc. has a mixed ownership structure, with approximately 22.88% of the company's stock owned by institutional investors, 27.52% by insiders, and 49.60% by public companies and individual investors. Major institutional owners include Polar Capital Holdings Plc, Orbimed Advisors Llc, Morgan Stanley, BlackRock, Inc., Soleus Capital Management, L.P., First Light Asset Management, LLC, Vanguard Group Inc, Armistice Capital, Llc, Driehaus Capital Management Llc, Deutsche Bank Ag, and KCK LTD. Among individual owners, Uri Geiger owns a significant number of shares, and other key executives and directors also hold shares, including Joel Becker (CEO), Dr. Martha J. Morrell M.D. (Chief Medical Officer), Patrick F. Williams (Chief Financial Officer), and Frank M. Fischer (Chairman of the Board).